Regenxbio Inc (RGNX)
REGENXBIO Inc. is a NASDAQ-listed common stock of a clinical-stage biotechnology company focused on gene therapy. The company develops treatments intended to deliver functional genes to cells affected by genetic disorders, using its proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. Its pipeline includes ABBV-RGX-314 for wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; RGX-202 for Duchenne muscular dystrophy; RGX-121 for mucopolysaccharidosis type II; and RGX-111 for mucopolysaccharidosis type I. REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company has collaboration and license agreements with AbbVie Global Enterprises Ltd. for ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. for RGX-121 and RGX-111 outside the United States. Incorporated in 2008, REGENXBIO is headquartered in Rockville, Maryland.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RGNX
|
$8.27
|
1.5% Upside
|
Fair
|
$23.73
|
191.1% Upside
|
Bargain
|
Fair
|
0.0%
|
November 11, 2026
|
7.5x
|
3.1x
|
538 M
|
683 M
|
32.5%
|
86.7%
|
-3.8
|
127.1%
|
